Drug details

Brineura (cerliponase alfa injection)

type of Metabolic & Endocrine, Other

Brineura (cerliponase alfa) injection is a hydrolytic lysosomal N-terminal tripeptidyl peptidase indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase1 (TPP1) deficiency.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• vomiting,
• fever,
• drowsiness,
• fussiness,
• neck stiffness,
• increased sensitivity to light,
• swelling, redness, or warmth in the child’s scalp,
• bulging or puffiness around the catheter,
• oozing or discharge around the catheter,
• fever with a headache,
• severe weakness, and
• any behavioral changes (lack of normal responses from your child)